Formycon AG (ETR:FYB)
24.90
-0.05 (-0.20%)
At close: Dec 8, 2025
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€192,296
Profits / Employee
€660,688
Market Cap
439.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 250 | 12 | 5.04% |
| Dec 31, 2023 | 238 | 33 | 16.10% |
| Dec 31, 2022 | 205 | 34 | 19.88% |
| Dec 31, 2021 | 171 | 40 | 30.53% |
| Dec 31, 2020 | 131 | 18 | 15.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
Formycon AG News
- 4 days ago - Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar - Nasdaq
- 4 days ago - EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Wallstreet:Online
- 14 days ago - EQS-News: NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy - Wallstreet:Online
- 18 days ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista
- 18 days ago - EQS-News: Ranibizumab Biosimilar Epruvy launched in Germany - Wallstreet:Online
- 21 days ago - EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent (dupilumab) adds another growth driver to the biosimilar portfolio - Wallstreet:Online
- 23 days ago - Formycon AG 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 24 days ago - Positioning Barbados as the Caribbean's Life Sciences Hub - Benzinga